Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Argenx SE    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AbbVie doubles down on cancer project with biotech group Argenx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2018 | 03:47am EDT

BRUSSELS (Reuters) - Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).

Following the announcement, Argenx shares rose by more than 6 percent in early trading.

Argenx, with bases in the Netherlands and Belgium, has several drugs to treat autoimmune diseases and cancer in various stages of medical trials, often in partnerships with large pharma groups.

It is also developing a cancer immunotherapy drug named ARGX-115 with AbbVie, for which the U.S. company has now decided to trigger an option which gives it an exclusive licence to develop and commercialise the drug.

ARGX-115 is in pre-clinical development, meaning it still has several stages of clinical trials to pass before it could enter the market.

After listing on the stock market in 2014, Argenx's share price has increased tenfold and it joined Belgium's blue-chip index Bel20 <.BFX> earlier this year.

(Reporting by Robert-Jan Bartunek; Editing by Mark Potter)

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE 3.50% 66.7 Delayed Quote.-30.11%
ARGENX SE 1.30% 125.1 Delayed Quote.44.95%
BEL 20 0.69% 3522.42 Real-time Quote.7.85%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARGENX SE
08/06argenx to Present at 2019 Wedbush PacGrow Healthcare Conference
GL
08/01ARGENX : reports half year 2019 financial results and second quarter business up..
PU
08/01argenx reports half year 2019 financial results and second quarter business ..
GL
07/25argenx to report half year 2019 financial results and second quarter business..
GL
05/30ARGEN X : argenx to Present at Upcoming Investor Conferences
PU
05/28ARGEN X : argenx announces publication of efgartigimod Phase 2 myasthenia gravis..
PU
05/23ARGEN X : argenx announces pipeline expansion and 'argenx 2021' vision to build ..
AQ
05/22ARGEN X : argenx announces pipeline expansion and “argenx 2021” visi..
PU
05/22ARGEN X : argenx announces pipeline expansion and “argenx 2021” visi..
AQ
05/16ARGEN X : argenx to Host R&D Day on May 22, 2019
AQ
More news
Financials (EUR)
Sales 2019 70,4 M
EBIT 2019 -150 M
Net income 2019 -135 M
Finance 2019 491 M
Yield 2019 -
P/E ratio 2019 -47,1x
P/E ratio 2020 -21,2x
EV / Sales2019 60,8x
EV / Sales2020 87,5x
Capitalization 4 767 M
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 133,75  €
Last Close Price 123,50  €
Spread / Highest target 21,5%
Spread / Average Target 8,30%
Spread / Lowest Target -2,83%
EPS Revisions
Managers
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGENX SE44.95%5 222
GILEAD SCIENCES0.94%79 622
VERTEX PHARMACEUTICALS11.60%46 554
REGENERON PHARMACEUTICALS-20.52%32 073
GENMAB26.56%13 013
SAREPTA THERAPEUTICS INC14.50%9 067